Medical technology company Implantica AG (Nasdaq First North Premier Growth Market: IMP A SDB) on Tuesday announced the publication of a landmark real-world study of its RefluxStop device in Scientific Reports, part of the Nature portfolio.

The study assessed 602 gastro-oesophageal reflux disease (GERD) patients treated across 22 European centres in six countries, with follow-up of up to 6.75 years.

Representing the largest and most comprehensive long-term safety evaluation of RefluxStop to date, the analysis found that more than 98% of patients experienced no serious safety issues requiring reoperation, with all reported events resolved satisfactorily.

The primary cause of reoperation was recurrence of repaired hiatal hernia, accounting for 1.33% of cases, while other serious events occurred in only one patient out of 602. The company noted recurrence rates in standard surgical procedures are approximately 10 times higher.

Lead author Prof. Sebastian Schoppmann presented the findings at the 2025 American Foregut Society Meeting, where the results received strong interest from US specialists ahead of a planned US launch pending regulatory approval.